Status: Not yet recruiting
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Participants needed: 45
Trial details
Phase: Phase 1Age: 18-25Biological sex: AllType: InterventionalSponsor: Vaccine Company, Inc.Updated: Apr 29, 2026Locations: 2
Eligibility criteria
Aged 18 to 25 years, inclusive [+1]
Self-reported or medically-documented significant medical or psychiatric conditi... [+5]